Equities

Belluscura PLC

Belluscura PLC

Actions
  • Price (EUR)0.184
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-52.08%
  • Beta--
Data delayed at least 15 minutes, as of May 16 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Belluscura PLC is a United Kingdom-based medical device developer company. The Company is focused on developing lightweight and portable oxygen enrichment technology. The Company's product X-PLOR, is a modular portable oxygen concentrator. The X-PLOR is lightweight, specifically designed to replace metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLOR can deliver up to 95% pure oxygen to patients 24 hours a day, seven days a week. The Company is focused on developing medical devices who suffer from chronic lung diseases, such as the Chronic Obstructive Pulmonary Disease (COPD), respiratory distress caused by COVID-19, and many other respiratory disorders. It is also focused on developing, licensing and manufacturing portable oxygen concentrators for use in treating lung diseases with its oxygen platform technologies, to include recreational and industrial oxygen concentrators, wound care devices, drug delivery devices and more.

  • Revenue in GBP (TTM)949.45k
  • Net income in GBP-7.90m
  • Incorporated2015
  • Employees24.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BELL:LSE since
announced
Transaction
value
TMT Acquisition PLCAnnounced03 Oct 202303 Oct 2023Announced-48.36%6.77m
Data delayed at least 20 minutes, as of May 17 2024 16:39 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.